Physician profile
Peter D Calder
NPI 1043201106
$1,141.23
in general payments reported to CMS, 2019-2025
15 companies · $124 in 2025
The $124 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128 · 2020: $68.06 · 2021: $79.58 · 2022: $268 · 2023: $316 · 2024: $158 · 2025: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $597.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $429.37 | 2019-2025 | Clareon, Hydrus Microstent, Rocklatan |
| Glaukos Corporation | $176.84 | 2022-2025 | Idosetr, Idose |
| Abbvie INC. | $164.48 | 2022-2024 | Lumigan, Alphagan P, Vuity |
| Bausch & Lomb Americas INC. | $75.41 | 2022-2023 | Amvisc Plus, Envista Mx60 Iol |
| Johnson & Johnson Surgical Vision, INC. | $49.54 | 2019-2022 | |
| Oyster Point Pharma, INC. | $41.70 | 2022-2023 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $35.73 | 2020 | |
| Tarsus Pharmaceuticals, INC. | $32.42 | 2024 | Xdemvy |
| Regeneron Healthcare Solutions, INC. | $31.75 | 2025 | Eylea Hd |
| Dompe US, INC. | $25.40 | 2025 | Oxervate |
| Shire North American Group INC | $18.92 | 2019 | |
| Allergan, INC. | $16.99 | 2021 | |
| Sun Pharmaceutical Industries INC. | $15.90 | 2024 | |
| Eyevance Pharmaceuticals LLC | $14.23 | 2023 | Flarex |
| New World Medical,INC. | $12.55 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Calder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.